May 20, 2025
In a bold strategic alliance, Regeneron and Sanofi have teamed up with AI healthcare innovator Viz.ai to tackle one of healthcare’s growing challenges: the rising burden of chronic obstructive pulmonary disease (COPD). This partnership integrates advanced artificial intelligence into COPD patient management, aiming to accelerate diagnosis, improve care pathways, and align with next-generation therapeutic development.
Strategic Use of AI to Identify High-Risk COPD Patients
The cornerstone of this collaboration is Viz.ai’s AI-driven workflow system, which uses cutting-edge natural language processing (NLP) to analyze unstructured clinical data within electronic health records (EHRs). This system is designed to identify patients at elevated risk for COPD exacerbations, enabling care teams to initiate timely and personalized interventions.
Aligning Digital Innovation with Drug Development
This AI deployment is strategically aligned with Regeneron and Sanofi’s co-development of itepekimab, a potential first-in-class antibody therapy for COPD. By rapidly surfacing eligible patients for clinical trials and, ultimately, therapy rollout, the partnership accelerates R&D timelines while maximizing patient targeting efficiency.
Operational Impact and Clinical Value
Integrating Viz.ai’s AI engine into routine clinical practice is expected to improve patient outcomes by reducing preventable hospitalizations and facilitating earlier intervention. For providers, it translates to optimized resource allocation and more precise care coordination—critical in chronic disease management.
Looking Ahead: A Scalable AI Framework for Chronic Disease
This initiative not only redefines COPD care but also establishes a scalable model for applying AI in other chronic disease areas. By marrying biopharma expertise with real-time data intelligence, Regeneron, Sanofi, and Viz.ai are setting a new benchmark in the AI-driven healthcare ecosystem.
This strategic initiative exemplifies the fusion of AI innovation and clinical expertise to create measurable value for patients, healthcare providers, and the broader life sciences industry.
For more details, refer to the official announcement from Viz.ai: Viz.ai
By
